Granisetron Transdermal Patch

DRUG3 trials

Sponsors

Gynecologic Oncology Group, University of Illinois at Chicago, Fudan University

Conditions

Chemotherapy-induced Nausea and Vomiting (CINV)Nausea With Vomiting Chemotherapy-InducedNausea and VomitingOvarian Brenner TumorOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mucinous CystadenocarcinomaOvarian Seromucinous Carcinoma

Phase 3

Granisetron Transdermal Patch for Prophylaxis of Delayed CINV

Fudan UniversityChemotherapy-induced Nausea and Vomiting (CINV)

Start: 2021-06-10End: 2023-12-30Target: 140Updated: 2021-06-03

Phase 4

BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron

RecruitingNCT04150614

University of Illinois at ChicagoNausea With Vomiting Chemotherapy-Induced

Start: 2020-05-14End: 2026-07-31Target: 90Updated: 2025-11-12

Unknown Phase

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

TerminatedNCT01275664

Gynecologic Oncology GroupNausea and Vomiting, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma +24

Start: 2011-06-30Updated: 2018-05-22

Related Papers

Granisetron Transdermal Delivery System Versus Palonosetron in the Prevention of Long-delayed Nausea and Vomiting: A Phase III Randomized Trial.

2026-01-10